New Drugs for Rheumatoid Arthritis | NEJM
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Cancers | Free Full-Text | Targeting NF-κB Signaling for Multiple Myeloma | HTML
Nuclear factor-κB: its role in health and disease | SpringerLink
NF-κB activation as a pathological mechanism of septic shock and inflammation | American Journal of Physiology-Lung Cellular and Molecular Physiology
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Individualization of leflunomide dosing in rheumatoid arthritis patients | Personalized Medicine
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis - ScienceDirect
Effect of leflunomide (2.5, 5 or10 mg/kg) on hepatic immunostaining for... | Download Scientific Diagram
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
Chemical structures of leflunomide and its metabolite A77 1726. | Download Scientific Diagram
NF-kappaB: a key role in inflammatory diseases. - Abstract - Europe PMC
Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review - ScienceDirect
Inhibiting NF-κB activation by small molecules as a therapeutic strategy. - Abstract - Europe PMC
Nuclear Factor κB Signaling in Atherogenesis | Arteriosclerosis, Thrombosis, and Vascular Biology
Frontiers | LncRNAs and Rheumatoid Arthritis: From Identifying Mechanisms to Clinical Investigation
Leflunomide Suppresses TNF-Induced Cellular Responses: Effects on NF-κB, Activator Protein-1, c-Jun N-Terminal Protein Kinase, and Apoptosis | The Journal of Immunology
Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis - Pharma Excipients
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function | Arthritis Research & Therapy | Full Text
Effects of Leflunomide on Hyaluronan Synthases (HAS): NF-κB-Independent Suppression of IL-1-Induced HAS1 Transcription by Leflunomide | The Journal of Immunology
Leflunomide–hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial - The Lancet Rheumatology
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis | Annals of the Rheumatic Diseases
